Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2003
05/22/2003WO2003042247A2 Modified anti-tnf alpha antibody
05/22/2003WO2003042246A2 Inhibitors of the notch signalling pathway for use in the treatment of cancer
05/22/2003WO2003042240A2 Polypeptides of pseudomonas aeruginosa
05/22/2003WO2003042239A1 Peptides inhibiting signaling by ras-like gtpases
05/22/2003WO2003042237A1 Peptide derivative, pharmaceutically acceptable salt thereof, process for producing the same, and use thereof
05/22/2003WO2003042226A2 Single nucleotide polymorphisms in gh-1
05/22/2003WO2003042197A1 Oligopeptides and compositions containing them as cathepsin s inhibitors
05/22/2003WO2003042163A1 N-methyl-homocystines, use thereof and method for the production thereof
05/22/2003WO2003041757A2 Catheter injectable depot compositions and uses thereof
05/22/2003WO2003041739A1 Anticaner agents
05/22/2003WO2003041738A1 Treatment of metabolic disorders with xitar agonists and antagonists
05/22/2003WO2003041737A1 Treatment of inflammatory conditions
05/22/2003WO2003041735A2 Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system
05/22/2003WO2003041730A1 Ditacin agonists and antagonists for use in the treatment of metabolic disorders
05/22/2003WO2003041729A1 Ptp1b inhibitors and ligands
05/22/2003WO2003041726A1 Use of an extracellular adherence protein for the manufacture of an anti-inflammatory drug
05/22/2003WO2003041725A2 Regulation of cgmp-specific phosphodiesterase 9a
05/22/2003WO2003041713A1 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
05/22/2003WO2003041694A2 Use of compounds comprising iodine, strontium and ascorbic acid as well as either bismuth, zinc or potassium in the treatment of aids
05/22/2003WO2003041689A1 Biocompatible polymer blends and uses thereof
05/22/2003WO2003041685A1 Injectable depot composition
05/22/2003WO2003041684A2 Injectable depot compositions and uses thereof
05/22/2003WO2003041680A1 Topical compositions containing enzymes stabilized with inhibitors
05/22/2003WO2003041657A2 Antisense modulation of vitamin d nuclear receptor expression
05/22/2003WO2003041655A2 Therapeutic agent composition and method of use
05/22/2003WO2003041652A2 Method of using 18080, a human serine carboxypeptidase family member
05/22/2003WO2003041640A2 METHODS FOR TREATING ISCHEMIC REPERFUSION INJURY USING IkB KINASE-BETA INHIBITORS
05/22/2003WO2003041635A2 Methods and compositions for therapeutic treatment of cathepsin k complex-mediated disorders
05/22/2003WO2003028646A3 Methods of treating drug-resistant bacterial infections
05/22/2003WO2003025541A3 Methods for treating multiple sclerosis
05/22/2003WO2003020763A3 Soluble t cell receptor
05/22/2003WO2003016497A3 Molecules for disease detection and treatment
05/22/2003WO2003016464A3 Cancer specific oligosaccharide sequences and use thereof
05/22/2003WO2003012089A3 Crystal structure of beta-site app cleaving enzyme (bace) and use thereof
05/22/2003WO2003011277A3 Methods to mobilize progenitor/stem cells
05/22/2003WO2003003904A3 Coactivators in the diagnosis and treatment of breast cancer
05/22/2003WO2002102987A3 Methods and compositions based on protein interactions with mastermind
05/22/2003WO2002102836A3 Moraxella (branhamella) catarrhalis antigens
05/22/2003WO2002100327A3 Substituted 1-benzazepines and derivatives thereof
05/22/2003WO2002097116A3 Delivery system for nucleic acids
05/22/2003WO2002094084A3 Bmpr1a involvement in juvenile polyposis
05/22/2003WO2002083120A3 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
05/22/2003WO2002081625A3 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
05/22/2003WO2002072754A3 Mva expressing modified hiv envelope, gag, and pol genes
05/22/2003WO2002068466A3 Hypoxia-regulated genes
05/22/2003WO2002061062A3 Human protein kinase n-like polypeptide and uses thereof
05/22/2003WO2002059369A3 Compositions and methods for the treatment of diseases related to faulty cholesterol regulation
05/22/2003WO2002058627A3 A cystic fibrosis transmembrane-conductance regulator (cftr)-membrane translocation sequence fusion protein (cftr-mts) as a therapeutic agent
05/22/2003WO2002055687A3 Transgenic mice containing target gene disruptions
05/22/2003WO2002053740A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/22/2003WO2002051430A3 Methods of modulating toll-related receptor (trr) signaling
05/22/2003WO2002050283A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
05/22/2003WO2002046768A3 Proteins, genes and their use for diagnosis and treatment of chronic asthma
05/22/2003WO2002031180A3 Flea peritrophin nucleic acid molecules, proteins and uses thereof
05/22/2003WO2002029050A3 Regulation of human secretin receptor-like gpcr
05/22/2003WO2002026780A3 Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
05/22/2003WO2002024215A3 Method for using activated protein c for the treatment of coagulation-associated disorders
05/22/2003WO2002024176A3 Treatment of tinnitus
05/22/2003WO2002022807A3 Dermatophagoides nucleic acid molecules, proteins and uses thereof
05/22/2003WO2002022776A9 Human coagulation factor vii variants
05/22/2003WO2002010389A3 Human ion channel proteins and polynucleotides encoding the same
05/22/2003WO2001086003A3 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human lung
05/22/2003WO2001079539A9 Method for using transfectable constructions from luciferase and from the promotor of the human period 1 gene for identifying novel active substances that influence the day/night rhythm and sleep
05/22/2003WO2001074298A3 Methods and compositions for regulating memory consolidation
05/22/2003WO2001070941A9 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
05/22/2003WO2001015736A3 Interferon-beta conjugates
05/22/2003WO2000037429A3 INHIBITORS OF α4β1 MEDIATED CELL ADHESION
05/22/2003US20030097669 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of Erk-5
05/22/2003US20030097668 Compositions and methods for the treatment and diagnosis of cardiovascular disease
05/22/2003US20030097667 For therapy of Alzheimers disease, diagnosis
05/22/2003US20030097665 To produce phosphorylated lysosomal proteins which are incorporated into pharmaceutical formulations for use in enzyme replacement therapy
05/22/2003US20030097011 Novel carbamate-based cationic lipids
05/22/2003US20030096982 Nucleotide sequences coding polypeptide for use in the treatment of immunological, reproductive and liver disorders
05/22/2003US20030096977 Antibody against human interleukin-5 receptor alpha chain
05/22/2003US20030096974 Transgenically produced antithrombin III
05/22/2003US20030096973 Recombinant collagens and derived proteins produced by plants, methods of obtaining such and their uses
05/22/2003US20030096969 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of cell proliferative and tumor disorders
05/22/2003US20030096957 AFX (zeta) transcription factor splice form
05/22/2003US20030096955 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of cancer and nervous system disorders
05/22/2003US20030096954 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of cancer and nervous system disorders
05/22/2003US20030096952 Novel proteins and nucleic acids encoding same
05/22/2003US20030096951 Polypeptide for use in the diagnosis and treatment of nervous sytem disorders
05/22/2003US20030096950 A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
05/22/2003US20030096949 Microbiocidal peptide for use in the treatment of respiratory system disorders
05/22/2003US20030096948 Acylating a destryptophan compound to obtain an ornithin amino protected compound, removing the ornithine protecting group; antibiotic daptomycin stereoisomeric compounds
05/22/2003US20030096869 Locating an artery which carries major blood supply to the tumor; intra-arterially injecting into the located artery a predetermined quantity of a polyunsaturated fatty acid solution and anti-antiogenic substances
05/22/2003US20030096857 Novel antidiabetic agents
05/22/2003US20030096852 Inhibiting binding interaction between hGH (human growth hormone) or a mutant thereof and an hGH binding protein or receptor in mammal administering benzimidazole compound
05/22/2003US20030096844 Cannabinoid receptor ligands
05/22/2003US20030096827 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition
05/22/2003US20030096795 Calcium (3S) tetrahydro-3-furanyl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phos-phonooxy)propylcarbamate
05/22/2003US20030096786 Methods of treating neurodegenerative or myelination disorders using prosaposin-derived peptides
05/22/2003US20030096785 Antisense agents to nucleic acids encoding human proteins (G protein-coupled receptors designated GPR12 and GPR3), which are expressed in the hypothalamus, to suppress hunger; antibodies, drug screening
05/22/2003US20030096784 Oligoribonucleotides and oligoribonucleosides that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase (double stranded RNAase)
05/22/2003US20030096783 21132, a human G-protein coupled receptor family member and uses therefor
05/22/2003US20030096782 Expression profiling in the intact human heart
05/22/2003US20030096781 Interleukin-8 (IL-8); antisense nucleotide targeted to IL-8 for rapid treatment without the associated cumulative toxicity of conventional treatments
05/22/2003US20030096780 High affinity IP3-binding polypeptide
05/22/2003US20030096779 High molecular weight Dermatophagoides proteins, and nucleic acids encoding them; used to treat and diagnose mite allergies
05/22/2003US20030096777 Antisense oligonucleotides which inhibit expression of a gene in operable association with protein effectors of that gene's product; DNA methyltransferase is inhibited at the genetic level as well as at the protein level; antitumor
1 ... 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 ... 3163